
|Articles|June 17, 2022
Daily Medication Pearl: Buprenorphine (Butrans)
Author(s)Saro Arakelians, PharmD
Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Advertisement
Medication Pearl of the Day: Buprenorphine (Butrans)
Indication: Buprenorphine (Butrans) is a partial opioid agonist indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Insight:
- Dosing: Doses of 7.5, 10, 15, and 20 mcg/hour are for opioid experienced patients only.
- Dosage forms: Transdermal system 5 mcg/hour, 7.5 mcg/hour, 10 mcg/hour, 15 mcg/hour, and 20 mcg/hour.
- Adverse events: Most common adverse reactions (≥ 5%) include nausea, headache, application site pruritus, dizziness, constipation, somnolence, vomiting, application site erythema, dry mouth, and application site rash.
- Mechanism of action: Buprenorphine is a partial agonist at mu opioid receptors.
Source:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Roflumilast Cream 0.3% for Plaque Psoriasis in Children as Young as 2
2
Do GLP-1 Receptor Agonists Increase the Risk of Smell and Taste Disturbances?
3
FDA Approves Tregzi for Adults With Hematological Malignancies
4
Early Recognition and Routine Discussion: Improving Outcomes in Tardive Dyskinesia
5












































































































